190 related articles for article (PubMed ID: 7909495)
1. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.
Press MF; Hung G; Godolphin W; Slamon DJ
Cancer Res; 1994 May; 54(10):2771-7. PubMed ID: 7909495
[TBL] [Abstract][Full Text] [Related]
2. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material.
van Diest PJ; Baak JP; Chin D; Theeuwes JW; Bacus SS
Anal Cell Pathol; 1991 Jul; 3(4):195-202. PubMed ID: 1679345
[TBL] [Abstract][Full Text] [Related]
4. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
[TBL] [Abstract][Full Text] [Related]
5. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
Pauletti G; Godolphin W; Press MF; Slamon DJ
Oncogene; 1996 Jul; 13(1):63-72. PubMed ID: 8700555
[TBL] [Abstract][Full Text] [Related]
6. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
Ross JS; Fletcher JA
Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.
Bigsby RM; Li AX; Bomalaski J; Stehman FB; Look KY; Sutton GP
Obstet Gynecol; 1992 Jan; 79(1):95-100. PubMed ID: 1345772
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu oncogene expression and proliferation in breast cancers.
Bacus SS; Ruby SG; Weinberg DS; Chin D; Ortiz R; Bacus JW
Am J Pathol; 1990 Jul; 137(1):103-11. PubMed ID: 1973597
[TBL] [Abstract][Full Text] [Related]
9. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
[TBL] [Abstract][Full Text] [Related]
10. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases.
Hanna W; Kahn HJ; Andrulis I; Pawson T
Mod Pathol; 1990 Jul; 3(4):455-61. PubMed ID: 1977159
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.
Bacus SS; Bacus JW; Slamon DJ; Press MF
Arch Pathol Lab Med; 1990 Feb; 114(2):164-9. PubMed ID: 1967930
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.
Vang R; Cooley LD; Harrison WR; Reese T; Abrams J
Am J Clin Pathol; 2000 May; 113(5):669-74. PubMed ID: 10800399
[TBL] [Abstract][Full Text] [Related]
13. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.
Gancberg D; Lespagnard L; Rouas G; Paesmans M; Piccart M; Di Leo A; Nogaret JM; Hertens D; Verhest A; Larsimont D
Am J Clin Pathol; 2000 May; 113(5):675-82. PubMed ID: 10800400
[TBL] [Abstract][Full Text] [Related]
16. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
17. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
[TBL] [Abstract][Full Text] [Related]
18. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu (c-erb-B2) gene and protein in breast cancer.
Ross JS; Fletcher JA
Am J Clin Pathol; 1999 Jul; 112(1 Suppl 1):S53-67. PubMed ID: 10396301
[TBL] [Abstract][Full Text] [Related]
20. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
